Orthobond
Private Company
Total funding raised: $105M
Overview
Orthobond is a private, pre-revenue medical device technology company founded in 2015, based in Monmouth Junction, New Jersey. It has developed a platform for creating covalently bound antimicrobial nanosurfaces that kill pathogens through mechanical rupture, avoiding antibiotics or chemical leaching. With recent funding, the company is advancing its lead program, Ostaguard™, toward FDA clearance for orthopedic implants while planning expansion into industrial, automotive, and consumer markets.
Technology Platform
Proprietary nanosurface modification for covalent binding of antimicrobial molecules to substrates; kills pathogens via mechanical rupture without eluting chemicals or antibiotics.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Orthobond competes in the antimicrobial coatings space against companies using technologies like silver ions, copper, and other chemical agents. Its key differentiator is a claimed permanent, covalently bound, non-eluting nanosurface that kills via physical disruption, potentially offering advantages in durability and avoiding resistance. It faces competition from both specialized startups and large materials science corporations.